Pelthos Therapeutics Inc.
Pelthos Therapeutics Inc., a bio-pharmaceutical company, develops and commercializes therapeutic products to help patients with unmet treatment burdens. The company offers ZELSUVMI for the treatment of molluscum contagiosum in adults and children 1 year of age and older. It also provides NITRICIL, a proprietary nitric oxide-based technology platform. The company was formerly known as Channel Ther… Read more
Pelthos Therapeutics Inc. (PTHS) - Total Assets
Latest total assets as of September 2025: $126.43 Million USD
Based on the latest financial reports, Pelthos Therapeutics Inc. (PTHS) holds total assets worth $126.43 Million USD as of September 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Pelthos Therapeutics Inc. - Total Assets Trend (2021–2024)
This chart illustrates how Pelthos Therapeutics Inc.’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Pelthos Therapeutics Inc. - Asset Composition Analysis
Current Asset Composition (December 2024)
Pelthos Therapeutics Inc.'s total assets of $126.43 Million consist of 100.0% current assets and 0.0% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 37.5% |
| Accounts Receivable | $40.40K | 3.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2021–2024)
This chart illustrates how Pelthos Therapeutics Inc.'s asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Pelthos Therapeutics Inc.'s current assets represent 100.0% of total assets in 2024, an increase from 0.0% in 2021.
- Cash Position: Cash and equivalents constituted 37.5% of total assets in 2024, up from 0.0% in 2021.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2021.
- Asset Diversification: The largest asset category is accounts receivable at 3.0% of total assets.
Pelthos Therapeutics Inc. Competitors by Total Assets
Key competitors of Pelthos Therapeutics Inc. based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
MedPacto Inc
KQ:235980
|
Korea | ₩51.58 Billion |
|
2H0
F:2H0
|
Germany | €15.27 Million |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥260.55 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.58 Billion |
|
Nanhua Bio Medicine Co Ltd
SHE:000504
|
China | CN¥841.96 Million |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
|
Hualan Biological EngineeringInc
SHE:002007
|
China | CN¥16.27 Billion |
Pelthos Therapeutics Inc. - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Pelthos Therapeutics Inc. generates 0.00x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Pelthos Therapeutics Inc. is currently not profitable relative to its asset base.
Pelthos Therapeutics Inc. - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.98 | 0.60 | 0.01 |
| Quick Ratio | 1.01 | 0.60 | 0.01 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $24.28 Million | $ -1.43 Million | $ -6.44 Million |
Pelthos Therapeutics Inc. - Advanced Valuation Insights
This section examines the relationship between Pelthos Therapeutics Inc.'s asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.14 |
| Latest Market Cap to Assets Ratio | 0.17 |
| Asset Growth Rate (YoY) | 1320.4% |
| Total Assets | $1.37 Million |
| Market Capitalization | $235.35K USD |
Valuation Analysis
Below Book Valuation: The market values Pelthos Therapeutics Inc.'s assets below their book value (0.17 x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: Pelthos Therapeutics Inc.'s assets grew by 1320.4% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Pelthos Therapeutics Inc. (2021–2024)
The table below shows the annual total assets of Pelthos Therapeutics Inc. from 2021 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $1.37 Million | +1320.41% |
| 2023-12-31 | $96.39K | +75.02% |
| 2022-12-31 | $55.07K | -- |
| 2021-12-31 | $0.00 | -- |